Cardinal Health Reports the Discontinuation of Biosimilar Infliximab & Switched Back to Remicade in the VA Study for Inflammatory Conditions
Shots:
- The US Veterans Healthcare Administration study helps to determine the patients who tried an infliximab biosimilar after being treated with Remicade & were switched to another innovator biologic in patients with RA, PsA, PsO, AS, CD & UC
- Of the 653 patients who switched off the biosimilar to another innovator biologic, 594 switched back to Remicade. The results were similar with Remicade & with RA and IBD & showed a median duration of follow-up of 796 & 337 days who switched to a biosimilar & continued to the reference infliximab
- Additionally, the results also showed that the patients who switched to the biosimilar had no increase in disease activity
Ref: Center for Biosimilars | Image: PR Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
